Amado J. Zurita

Featured in: Favicon

nature.com Favicon

thelancet.com Favicon

Articles

Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial - Nature Communications

Jan 9, 2025 | nature.com | Pavlos Msaouel |Rahul Sheth |Amishi Y. Shah |Amado J. Zurita |Giannicola Genovese |Minghao Dang | +3 more

AbstractWe conducted a phase I trial to determine the optimal dose of triplet therapy with the tyrosine kinase inhibitor sitravatinib plus nivolumab plus ipilimumab in 22 previously untreated patients with advanced clear cell renal cell carcinoma. The primary endpoint was safety.
Body composition as a determinant of the therapeutic index with androgen signaling inhibition - Prostate Cancer and Prostatic Diseases

Jul 16, 2024 | nature.com | Andrew Hahn |Rebecca S. Tidwell |Amado J. Zurita |Sumit K. Subudhi |Pavlos Msaouel |Efstratios Koutroumpakis | +2 more

AbstractAndrogen signaling is central to prostate cancer and men’s health. Prior data indicates that increasing body fat is unfavorable in the localized setting yet associated with favorable outcomes in men with metastatic disease. Understanding the biological links between adiposity and prostate cancer may optimize the therapeutic index with ASI.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →